Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma.

Yang, Yanjie; Du, Nan; Ma, Jingqin; Peng, Zhijie; Zhou, Bo; Yu, Jiaze; Zhou, Xin; Zhang, Wen; Yan, Zhiping

Yang, Yanjie; Du, Nan; Ma, Jingqin; Peng, Zhijie; Zhou, Bo; Yu, Jiaze; Zhou, Xin; Zhang, Wen; Yan, Zhiping.

Afiliación

Yang Y; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Du N; Shanghai Institute of Medical Imaging, Fudan University, Shanghai, People's Republic of China.
Ma J; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Peng Z; Shanghai Institute of Medical Imaging, Fudan University, Shanghai, People's Republic of China.
Zhou B; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Yu J; Shanghai Institute of Medical Imaging, Fudan University, Shanghai, People's Republic of China.
Zhou X; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Zhang W; Shanghai Institute of Medical Imaging, Fudan University, Shanghai, People's Republic of China.
Yan Z; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

J Hepatocell Carcinoma ; 10: 1897-1910, 2023.

Article en En | MEDLINE | ID: mdl-37904836

ABSTRACT

ABSTRACT

Objective:

This study aimed to assess the treatment response, survival outcomes, and safety of a novel transarterial chemoembolization (TACE) technique with a three-stage mixed chemoembolic regimen (M-TACE) in patients with large unresectable hepatocellular carcinoma (HCC) measuring more than 5 cm in maximum diameter.

Methods:

Between January 2017 and March 2023, a total of 82 patients were enrolled in this retrospective cohort study. Treatment response was assessed in the first month after M-TACE; progression-free survival and overall survival (OS) were evaluated. The prognostic factors associated with patient survival were statistically analyzed by the Cox regression model. Adverse events were recorded.

Results:

The maximum diameter of the tumors ranged from 5.3 cm to 20.0 cm (mean 10.71 cm). The objective response (OR) and disease control rates were 74.4 and 92.7%, respectively, at 1-month follow-up. The median survival time was 22 months (95% CI, 13.10-30.90 months). The OS rates were 82.0% at six months, 62.5% at one year, and 43.0% at two years. Targeted therapy and/or immunotherapy (P=0.001) and tumor response at one month (P=0.020) were protective factors for OS. In terms of safety, no major complications occurred and the only observed decrease within the normal range occurred in albumin and platelet levels one month after the embolization procedure. This decrease in levels did not show a significant relationship with the OR rates.